Pluronic® triblock copolymer-based nanoformulations for cancer therapy: A 10-year overview

J Control Release. 2023 Jan:353:802-822. doi: 10.1016/j.jconrel.2022.12.017. Epub 2022 Dec 17.

Abstract

This paper provides a review of the literature on the use of Pluronic® triblock copolymers for drug encapsulation over the last 10 years. A special focus is given to the progress of drug delivery systems (e.g., micelles, liposomes, micro/nanoemulsions, hydrogels and nanogels, and polymersomes and niosomes); the beneficial aspects of Pluronic® triblock copolymers as biological response modifiers and as pharmaceutical additives, adjuvants, and stabilizers, are also discussed. The advantages and limitations encountered in developing site-specific targeting approaches based on Pluronic-based nanostructures in cancer treatment are highlighted, in addition to innovative examples for improving tumor cytotoxicity while reducing side effects.

Keywords: Amphiphilic copolymers; Cancer therapy; Drug delivery systems (DDS); Nanostructures (NSs); Pluronic®; Self-assembly.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Delivery Systems
  • Humans
  • Micelles
  • Neoplasms* / drug therapy
  • Poloxamer* / chemistry
  • Polymers / chemistry

Substances

  • Poloxamer
  • Polymers
  • Micelles